trial · primary record
Pembrolizumab
Non-small Cell Lung Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 851 |
| Primary completion | 2031-08-15 |
| Primary endpoint | Overall survival (OS) |
| Registry ID | NCT06422143 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:28:34.981Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06422143
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.